沙库巴曲缬沙坦对单剂量呋塞米药代动力学和药效学的影响
本研究在健康受试者中评估沙库巴曲缬沙坦对呋塞米药代动力学和药效学的影响。开放标签、两周期、单序列设计,28名受试者先单用呋塞米40mg,后合用沙库巴曲缬沙坦200mg每日两次共5天。结果显示合用降低呋塞米Cmax、AUC和24小时尿排泄,但药效学效应无显著影响。
要点
- 沙库巴曲缬沙坦降低呋塞米血浆峰浓度和暴露量及24小时尿排泄。
- 合用对呋塞米利尿和促钠排泄效应无显著影响。
- PARADIGM-HF事后分析显示沙库巴曲缬沙坦组呋塞米中位剂量基线与研究结束时相似。
核心结论
- 沙库巴曲缬沙坦降低呋塞米血浆Cmax和AUC及24小时尿排泄,但在健康受试者中未显著影响其药效学效应。
研究设计与样本
- 开放标签、两周期、单序列研究,纳入健康受试者28名。
- 第一周期单用呋塞米40mg口服,洗脱2天;第二周期沙库巴曲缬沙坦200mg(97/103mg)每日两次共5天,第6天合用单剂量呋塞米40mg。
主要发现
- 合用沙库巴曲缬沙坦后呋塞米Cmax几何均值比(90%CI)为0.50(0.44,0.56)。
- 呋塞米AUC0-∞几何均值比(90%CI)为0.72(0.67,0.77)。
- 呋塞米24小时尿排泄几何均值比(90%CI)为0.74(0.69,0.79)。
- 合用后呋塞米0-4h、4-8h和0-24h利尿分别降低约7%、21%和0.2%,促钠排泄分别降低约28.5%、7%和15%。
- PARADIGM-HF事后分析显示沙库巴曲缬沙坦组呋塞米中位剂量在基线和研究结束时相似。
临床怎么用
- 临床合用沙库巴曲缬沙坦与呋塞米时,无需因药代动力学相互作用调整呋塞米剂量,但需关注利尿效果个体差异。
局限性
- 研究在健康受试者中进行,非心力衰竭患者。
- 单剂量呋塞米设计,未评估长期合用效应。
- 开放标签、单序列设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Sacubitril/valsartan is indicated for the treatment of heart failure and reduced ejection fraction (HFrEF). Furosemide, a loop diuretic commonly used for the treatment of HFrEF, may be coadministered with sacubitril/valsartan in clinical practice. The effect of sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of furosemide was evaluated in this open label, two-period, single-sequence study in healthy subjects. METHODS: All subjects (n = 28) received 40 mg oral single-dose furosemide during period 1, followed by a washout of 2 days. In period 2, sacubitril/valsartan 200 mg (97/103 mg) was administered twice daily for 5 days and a single dose of 40 mg furosemide was coadministered on day 6. Serial plasma and urine samples were collected to determine the pharmacokinetics of furosemide and sacubitril/valsartan and the pharmacodynamics of furosemide. The point estimates and the associated 90% confidence intervals for pharmacokinetic parameters were evaluated. RESULTS: Coadministration of furosemide with sacubitril/valsartan decreased the maximum observed plasma concentration (Cmax ) [estimated geometric mean ratio (90% confidence interval): 0.50 (0.44, 0.56)], area under the plasma concentration-time curve (AUC) from time 0 to infinity [0.72 (0.67, 0.77)] and 24-h urinary excretion of furosemide [0.74 (0.69, 0.79)]. When coadministered with sacubitril/valsartan, 0-4-h, 4-8-h and 0-24-h diuresis in response to furosemide was reduced by ~7%, 21% and 0.2%, respectively, while natriuresis was reduced by ~ 28.5%, 7% and 15%, respectively. Post hoc analysis of the pivotal phase III Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) indicated that the median furosemide dose was similar at baseline and at the end of the study in the sacubitril/valsartan group. CONCLUSIONS: Sacubitril/valsartan reduced plasma Cmax and AUC and 24-h urinary excretion of furosemide, while not significantly affecting its pharmacodynamic effects in healthy subjects.
引用
- Ayalasomayajula S, Schuehly U, Pal P, et al. Effect of the angiotensin receptor-neprilysin inhibitor sacubitril/valsartan on the pharmacokinetics and pharmacodynamics of a single dose of furosemide. Br J Clin Pharmacol. 2018. PMID: 29318651. doi:10.1111/bcp.13505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。